Oligonucleotides: An Emerging Modality for Life-Altering CNS Outcomes
In a landscape where traditional treatments often fall short, oligonucleotide therapeutics emerge as game-changers, offering precise targeting and potentially life-altering outcomes.
With Biogen’s investigational ASO BIIB080 clinically reducing tau pathology in AD, Roche and Denali’s ASO conjugate delivery platforms offering less invasive administration routes on intrathecal delivery and Alnylam’s siRNA dominance, and pharma and biotech investing in this modality for CNS, 2024 is set to be an exciting year for oligonucleotide breakthroughs.
Now it’s time to double down on the biggest industry bottlenecks limiting pipeline progress: delivery, toxicity, formulation, and distribution.
With 27+ KOLs speaking on the program from the likes of Roche, Janssen, Merck, and Novartis, the 4th Oligonucleotides for CNS Summit is the ultimate biopharma-led meeting dedicated to overcoming industry-specific challenges.
Neurobiologists & Structural Chemists United to:
Exploring cutting-edge innovations in oligonucleotide delivery, delving into less invasive techniques beyond intrathecal delivery. Gain insights into comparative distribution, affinity, efficacy, and specificity through discussions with industry leaders from Genentech, ArtheX Biotech, Roche, Biorchestra, and Northeastern University.
Discovering pivotal advancements in achieving uniform distribution of ASOs and siRNAs, enabling deeper penetration into various brain regions for diverse CNS indications. Learn from Stoke Therapeutics, Roche, and Bolden Therapeutics about breakthroughs in vivo and in human studies.
Refining your oligonucleotide target discovery and validation methodologies using AI & ML technologies. Optimize the chemistry of oligonucleotide ASOs, siRNAs, and saRNAs to develop safer, more specific, and efficacious drugs with insights from Creyon Bio, Amylyx, and Bolden Therapeutics.
Validating the translational efficacy and safety of oligonucleotides through robust preclinical models, ensuring greater proof of concept before clinical trials. Gain valuable insights from AcuraStem, and Everyone Medicines, while effectively managing oligonucleotide toxicity through enhanced chemistry and scaffolding techniques with Apellis Pharma and Everyone Medicines.
Improving oligonucleotide chemistry, formulation, and stability through forced degradation studies and optimization techniques. Enhance stability and manage CDMO relationships effectively with expertise from CAMP4 Therapeutics and Amylyx Pharmaceutical.
Who Attended?
The 4th Oligonucleotides for CNS meeting unites 150+ key pharma and biotech across structural chemists, discovery biologists, CMC experts, preclinical scientists, clinical leaders, and regulatory professionals.
From C-Level executives to senior scientists, come together this July to hear the latest unpublished data, heated panel discussions, and deep-dive workshops you won’t find anywhere else.